McKesson Corporation (MCK)
- Previous Close
532.00 - Open
531.64 - Bid 531.16 x 1300
- Ask 531.76 x 800
- Day's Range
529.48 - 533.83 - 52 Week Range
352.34 - 543.00 - Volume
76,320 - Avg. Volume
681,867 - Market Cap (intraday)
69.615B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
23.94 - EPS (TTM)
22.13 - Earnings Date May 7, 2024
- Forward Dividend & Yield 2.48 (0.47%)
- Ex-Dividend Date Feb 29, 2024
- 1y Target Est
571.56
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
www.mckesson.com45,000
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: MCK
Performance Overview: MCK
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MCK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MCK
Valuation Measures
Market Cap
69.91B
Enterprise Value
75.54B
Trailing P/E
24.05
Forward P/E
17.15
PEG Ratio (5yr expected)
5.05
Price/Sales (ttm)
0.24
Price/Book (mrq)
--
Enterprise Value/Revenue
0.25
Enterprise Value/EBITDA
17.02
Financial Highlights
Profitability and Income Statement
Profit Margin
0.99%
Return on Assets (ttm)
3.63%
Return on Equity (ttm)
--
Revenue (ttm)
301.51B
Net Income Avi to Common (ttm)
3B
Diluted EPS (ttm)
22.13
Balance Sheet and Cash Flow
Total Cash (mrq)
1.98B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
3.03B
Research Analysis: MCK
Company Insights: MCK
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: MCK
The Argus Innovation Model Portfolio
The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the current period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as vaccines and AI) and services (such as Zoom calls) and moving into new markets, the domestic economy would not be growing, and capital would not be flooding into the country. The current high level of the U.S. dollar relative to currencies around the world attests to the confidence that global investors have in the durable and innovative U.S. economy.
Analyst Report: Mckesson Corporation
McKesson, which is headquartered in Irving, Texas, operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, and biosimilar pharmaceutical drugs. The RxTS segment provides access solutions, such as prior authorizations, and third-party logistics. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson has divested most of its operations in Europe.
RatingPrice TargetMarket Digest: ILMN, DIS, MCK, YUM, CAVA
The daily charts for the major indices all have a 'rolling-over' look, with the Nasdaq and Nasdaq 100 (QQQ) appearing to be ahead of the S&P 500 (SPX) for a break lower. As well, the news from the Middle East seems to be getting worse by the day -- but, so far, the U.S stock market and economy seem to be turning a blind eye to the potential implications. Crude oil prices, both WTI and Brent, aren't exploding, but have seen pretty good rallies. WTI hit $87.60/barrel at the end of last week from the low $70s just two months ago, while Brent almost reached $92 last week from $77 in early February.
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.